Table S4.
Current treatment by CAT score domain in China
| Overall (N=511) | 0–9 (n=9) | 10–19 (n=88) | 20–29 (n=304) | 30–40 (n=110) | |
|---|---|---|---|---|---|
| Current treatment, n (%) | |||||
| Missing, n | 1 | 0 | 0 | 0 | 1 |
| Single short-acting therapy | |||||
| SABA, SAMA, SABA/SAMA alone | 19 (3.7) | 1 (11.1) | 5 (5.7) | 9 (3.0) | 4 (3.7) |
| Maintenance therapies | |||||
| Bronchodilator monotherapy | |||||
| LAMA alone | 4 (0.8) | 0 | 0 | 3 (1.0) | 1 (0.9) |
| LABA alone | 5 (1.0) | 0 | 0 | 4 (1.3) | 1 (0.9) |
| Bronchodilator dual therapy | |||||
| LABA+LAMA | 1 (0.2) | 0 | 0 | 1 (0.3) | 0 |
| Triple therapya | |||||
| ICS/LABA+LAMA | 8 (1.6) | 0 | 1 (1.1) | 2 (0.7) | 5 (4.6) |
| LAMA+LABA+ICS | 0 | 0 | 0 | 0 | 0 |
| ICS-based therapies not including dual LA MA+LABA component | |||||
| ICS alone | 11 (2.2) | 1 (11.1) | 2 (2.3) | 4 (1.3) | 4 (3.7) |
| ICS/LABA alone | 132 (25.9) | 5 (55.6) | 15 (17.0) | 83 (27.3) | 29 (26.6) |
| ICS+LAMA | 0 | 0 | 0 | 0 | 0 |
| ICS+LABA | 4 (0.8) | 0 | 0 | 1 (0.3) | 3 (2.8) |
| ICS/LABA+LABA | 4 (0.8) | 0 | 0 | 2 (0.7) | 2 (1.8) |
| ICS/LABA+LTRA | 54 (10.6) | 0 | 15 (17.1) | 30 (9.9) | 9 (8.3) |
| ICS/LABA+xanthines | 103 (20.2) | 1 (11.1) | 10 (11.4) | 70 (23.0) | 22 (20.2) |
| ICS/LABA+ICS | 2 (0.4) | 0 | 0 | 2 (0.7) | 0 |
| ICS/LABA+ICS+LTRA | 2 (0.4) | 0 | 2 (2.3) | 0 | 0 |
| ICS/LABA+ICS+xanthines | 1 (0.2) | 0 | 0 | 1 (0.3) | 0 |
| ICS+xanthines | 28 (5.5) | 0 | 4 (4.6) | 21 (6.9) | 3 (2.8) |
| ICS+LTRA | 3 (0.6) | 0 | 1 (1.1) | 1 (0.3) | 1 (0.9) |
| Other maintenance therapy | |||||
| ICS/LABA+ICS | 2 (0.4) | 0 | 0 | 2 (0.7) | 0 |
| LTRA alone | 13 (2.6) | 0 | 3 (3.4) | 8 (2.6) | 2 (1.8) |
| Xanthines alone | 57 (11.2) | 0 | 16 (18.2) | 30 (9.9) | 11 (10.1) |
| LABA+xanthines | 13 (2.6) | 0 | 5 (5.7) | 7 (2.3) | 1 (0.9) |
| ICS/LABA+LABA+LAMA | 0 | 0 | 0 | 0 | 0 |
| ICS/LABA+ICS+LAMA | 0 | 0 | 0 | 0 | 0 |
| Other | 46 (9.0) | 1 (11.1) | 9 (10.2) | 25 (8.2) | 11 (10.1) |
Note:
a
Triple therapy defined as a single LABA, a single LAMA and a single ICS therapy only.
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.